Document is current
Any future updates will be listed below
-
Authors
Hsia, Oliver
Hinterndorfer, Matthias https://orcid.org/0000-0003-2435-4690
Cowan, Angus D. https://orcid.org/0000-0002-9702-7319
Iso, Kentaro https://orcid.org/0000-0001-5417-3642
Ishida, Tasuku https://orcid.org/0000-0001-7592-7925
Sundaramoorthy, Ramasubramanian
Nakasone, Mark A. https://orcid.org/0000-0002-1362-191X
Imrichova, Hana https://orcid.org/0000-0003-0385-1823
Schätz, Caroline
Rukavina, Andrea https://orcid.org/0000-0001-8254-9360
Husnjak, Koraljka https://orcid.org/0000-0003-0573-6239
Wegner, Martin https://orcid.org/0000-0001-6403-3926
Correa-Sáez, Alejandro https://orcid.org/0000-0001-5240-4865
Craigon, Conner
Casement, Ryan
Maniaci, Chiara
Testa, Andrea https://orcid.org/0000-0002-8973-9711
Kaulich, Manuel https://orcid.org/0000-0002-9528-8822
Dikic, Ivan https://orcid.org/0000-0001-8156-9511
Winter, Georg E. https://orcid.org/0000-0001-6606-1437
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
- License Information
-
More Information
Article History
Received: 18 February 2023
Accepted: 18 January 2024
First Online: 21 February 2024
Competing interests
: A.C. is a scientific founder, shareholder and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. A.T. is currently an employee of Amphista Therapeutics. G.E.W. is scientific founder and shareholder of Proxygen and Solgate. The Winter laboratory has received research funding from Pfizer. The other authors declare no competing interests.
